Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States? [PDF]
BioDrugs, 2020 Alvarez DF +4 more
europepmc +1 more source
Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases. [PDF]
Ther Adv Gastroenterol, 2016 Sieczkowska J +4 more
europepmc +1 more source
Insights on the use of biosimilars in the treatment of inflammatory bowel disease. [PDF]
World J Gastroenterol, 2017 Zheng MK, Shih DQ, Chen GC.
europepmc +1 more source
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. [PDF]
Ann Rheum Dis, 2013 Park W +13 more
europepmc +1 more source
Comparative efficacy and safety of biosimilar infliximab and other biological treatments in ankylosing spondylitis: systematic literature review and meta-analysis. [PDF]
Eur J Health Econ, 2014 Baji P +6 more
europepmc +1 more source
Spanish Readers Skip Articles Regardless of Gender and Number Agreement. [PDF]
J Eye Mov ResSerrano-Carot M, Angele B.
europepmc +1 more source
CT-P13: design, development, and place in therapy. [PDF]
Drug Des Devel Ther, 2017 Gabbani T, Deiana S, Annese V.
europepmc +1 more source
Biosimilars: what's around the corner? [PDF]
Frontline Gastroenterol, 2015 Russell RK, Irving P, Probert C.
europepmc +1 more source
Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis. [PDF]
RMD Open, 2019 Lindström U +11 more
europepmc +1 more source